Search Results

HBV Immunotherapeutic Vaccines (Lessons from HCV) - E. Barnes, PhD, FRCP, F. Med. Sci.

HBV Immunotherapeutic Vaccines (Lessons from HCV) - E. Barnes, PhD, FRCP, F. Med. Sci.

VBI-2601: Immunotherapeutic HBV Vaccine Candidate Overview - F. Diaz-Mitoma, MD, PhD

VBI-2601: Immunotherapeutic HBV Vaccine Candidate Overview - F. Diaz-Mitoma, MD, PhD

STOP Agents - M. McClure, MD

STOP Agents - M. McClure, MD

Core Inhibitors (Capsid Assembly Modulators) - L. Stamm, MD, PhD

Core Inhibitors (Capsid Assembly Modulators) - L. Stamm, MD, PhD

HBsAg Loss: A Predictor of Long-Term Clinical Outcomes - M. Peters, MD

HBsAg Loss: A Predictor of Long-Term Clinical Outcomes - M. Peters, MD

New Combination Therapies in Hepatitis Delta Therapy - J. Glenn, MD, PhD

New Combination Therapies in Hepatitis Delta Therapy - J. Glenn, MD, PhD

New Data From Combination Trials for Chronic Hepatitis B - Pietro Lampertico, MD, PhD

New Data From Combination Trials for Chronic Hepatitis B - Pietro Lampertico, MD, PhD

Safety Monitoring during HBV Clinical Trials and after Antiviral Discontinuation -P. Mishra, MD

Safety Monitoring during HBV Clinical Trials and after Antiviral Discontinuation -P. Mishra, MD

Patient Selection for Clinical Trials Based on Drug Class - F. Zoulim, MD, PhD

Patient Selection for Clinical Trials Based on Drug Class - F. Zoulim, MD, PhD

MD Insights: Dr. Florian Rieder

MD Insights: Dr. Florian Rieder